Rixathon

Rixathon (GP2013) is a biosimilar chimeric monoclonal antibody that targets the CD20 antigen, a protein primarily expressed on the surface of B-lymphocytes. Developed by Sandoz, Rixathon was the first rituximab biosimilar to receive approval in the European Union (June 2017) for all indications of the reference product, MabThera/Rituxan. Its mechanism of action involves binding to CD20 and inducing B-cell depletion through complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and the induction of apoptosis. Rixathon is indicated for the treatment of various B-cell malignancies, including follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia, as well as autoimmune disorders such as rheumatoid arthritis and certain types of vasculitis. Although Sandoz withdrew its Biologics License Application (BLA) in the United States in 2018, the drug is widely marketed in Europe and other regions.

Brand names

RixathonRiximyo

Other names

rituximab-SandozGP-2013GP2013GP 2013